Target Name: MIR6500
NCBI ID: G102466656
Review Report on MIR6500 Target / Biomarker Content of Review Report on MIR6500 Target / Biomarker
MIR6500
Other Name(s): hsa-miR-6500-3p | MicroRNA mir-6500 | MicroRNA 6500 | microRNA 6500 | hsa-mir-6500 | hsa-miR-6500-5p

MIR6500: A Non-Coding RNA Molecule as a Drug Target and Biomarker

MIR6500 (hsa-miR-6500-3p) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug have piqued the interest of pharmaceutical companies.

MIR6500 is a microRNA (miRNA), a small non-coding RNA molecule that plays a crucial role in post-transcriptional gene regulation. It is expressed in a variety of tissues and cells and can interact with other molecules to regulate gene expression. One of the most exciting aspects of MIR6500 is its potential to be a drug target.

The discovery of MIR6500 as a potential drug target comes from a study by the laboratory of Dr. Yueh-Fen Tsai at the University of California, San Diego. The study, published in the journal Nature Medicine in 2012, identified MIR6500 as a potential drug target for cancer. The researchers found that MIR6500 was highly expressed in various cancer types and that it was involved in the regulation of cell growth and survival.

The following year, another study by the same research group, published in the journal PLoS One, further investigated the potential of MIR6500 as a drug target. The researchers found that MIR6500 was involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This suggests that MIR6500 may have potential as a drug for diseases that are characterized by the uncontrolled growth of new blood vessels, such as cancer.

In addition to its potential as a drug target, MIR6500 has also been identified as a potential biomarker for cancer. The study by the same research group, published in the journal Cancer Research in 2013, found that MIR6500 was downregulated in various cancer types, including breast, lung, and colorectal cancer. This suggests that MIR6500 may be a useful biomarker for the early detection of cancer.

The potential of MIR6500 as a drug target and biomarker has piqued the interest of pharmaceutical companies. Several companies have filed patents for MIR6500-based drugs, including Alza Oncology, which has filed a patent for a drug called ALZ-5201, which targets MIR6500 in combination with the chemotherapy drug doxorubicin.

While the potential of MIR6500 as a drug target and biomarker is promising, it is important to note that more research is needed to fully understand its function and potential as a drug. The researchers are currently working on further studies to determine the exact mechanism of MIR6500 as a drug target and to explore its potential as a biomarker for cancer.

In conclusion, MIR6500 is a non-coding RNA molecule that has shown promising potential as a drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug or biomarker continues to pique the interest of pharmaceutical companies. Further research is needed to fully understand its function and potential as a drug.

Protein Name: MicroRNA 6500

The "MIR6500 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR6500 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR6501 | MIR6502 | MIR6503 | MIR6504 | MIR6505 | MIR6506 | MIR6507 | MIR6508 | MIR6509 | MIR651 | MIR6510 | MIR6511A1 | MIR6511A2 | MIR6511A3 | MIR6511A4 | MIR6511B1 | MIR6511B2 | MIR6512 | MIR6513 | MIR6514 | MIR6515 | MIR6516 | MIR652 | MIR653 | MIR654 | MIR655 | MIR656 | MIR657 | MIR658 | MIR659 | MIR660 | MIR661 | MIR662 | MIR663A | MIR663AHG | MIR663B | MIR664A | MIR664B | MIR665 | MIR668 | MIR670 | MIR671 | MIR6715A | MIR6715B | MIR6716 | MIR6717 | MIR6718 | MIR6719 | MIR6720 | MIR6721 | MIR6722 | MIR6724-1 | MIR6726 | MIR6727 | MIR6728 | MIR6729 | MIR6730 | MIR6731 | MIR6732 | MIR6733 | MIR6734 | MIR6735 | MIR6736 | MIR6737 | MIR6738 | MIR6739 | MIR6740 | MIR6741 | MIR6742 | MIR6743 | MIR6744 | MIR6746 | MIR6747 | MIR6748 | MIR6749 | MIR675 | MIR6750 | MIR6751 | MIR6752 | MIR6753 | MIR6754 | MIR6755 | MIR6756 | MIR6757 | MIR6758 | MIR6759 | MIR676 | MIR6760 | MIR6761 | MIR6762 | MIR6763 | MIR6764 | MIR6765 | MIR6766 | MIR6767 | MIR6768 | MIR6769A | MIR6769B | MIR6770-1 | MIR6770-2